Related Experiment Video
Updated: Jun 3, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Identification of new genes associated with melanoma
Andreas Mauerer1, Alexander Roesch, Christian Hafner
1Department of Dermatology, University of Regensburg, Regensburg, Germany.
Purpose:
Repeated failures in melanoma therapy made clear that the molecular mechanisms leading to melanoma are still poorly understood. In this study, we aim to provide a more comprehensive understanding of the transcriptional profiles and signalling pathways associated with melanoma.
Methods:
Gene expression was analysed using the Affymetrix Human Genome U133A 2.0 GeneChip arrays. To avoid culture artifacts, we used microdissected fresh frozen material of 18 melanocytic nevi (MN), 20 primary melanomas (PM) and 20 metastatic melanomas (MM). Statistical analysis was performed with Genomatix Chipinspector, Ingenuity™ Software, SPSS Software and Partek Genomic Suite 6.4. Expression levels of selected transcripts were verified by quantitative real-time RT-PCR and immunostaining of a tissue microarray sampling more than 280 cases of MN, PM and MM with known clinical outcome.
Results:
A total of 284 differentially expressed genes was detected in PM compared with MN and 189 genes in MM compared with PM affecting common cancer pathways such as MAPK-, Wnt- and Notch-signalling. Using principal component analysis, the samples could be grouped according to their histological entity. We identified a panel of novel melanoma-associated markers: frizzled-related protein, an antagonist of Wnt; tranducin-like enhancer of split 1, a transcription factor partner of TCF/LEF-1; CNTN1, an activator of Notch signalling; two Serpin peptidase inhibitors, Serpin B3/B4 and the TGF-β family member GDF15, the latter with association to MAPK-signalling.
Insights
This study reveals novel molecular markers and pathways in melanoma progression. Understanding these melanoma transcriptional profiles and signaling pathways can improve future therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Melanoma therapy often fails due to poorly understood molecular mechanisms.
- A deeper understanding of melanoma's transcriptional landscape is crucial for therapeutic advancements.
Purpose of the Study:
- To comprehensively analyze transcriptional profiles in melanoma.
- To identify key signaling pathways involved in melanoma development and metastasis.
Main Methods:
- Gene expression analysis using Affymetrix arrays on fresh frozen microdissected tissues (melanocytic nevi, primary melanoma, metastatic melanoma).
- Statistical analysis with specialized software (Genomatix, Ingenuity™, SPSS, Partek).
- Validation of transcript expression via quantitative real-time RT-PCR and immunostaining on a large tissue microarray.
Main Results:
- Identified 284 differentially expressed genes in primary melanoma vs. nevi and 189 in metastatic vs. primary melanoma.
- Detected alterations in key cancer pathways including MAPK, Wnt, and Notch signaling.
- Discovered novel melanoma markers: frizzled-related protein, tranducin-like enhancer of split 1, CNTN1, Serpin B3/B4, and GDF15.
Conclusions:
- The study provides a detailed molecular signature of melanoma progression.
- Identified novel biomarkers associated with Wnt, Notch, and MAPK signaling pathways in melanoma.
- Findings offer potential targets for improved melanoma diagnosis and treatment strategies.
